By Lisa Kerner
Charlotte, N.C., Oct. 31 - Esperance Pharmaceuticals Inc. closed a $9 million round of series A financing.
Proceeds will be used to identify a lead compound, establish an assay to select candidate patients and conduct a proof-of-concept study in humans with cancer.
Louisiana Fund I, Themelios Ventures Partners LP and Research Corporation Technologies Inc. (RCT) co-lead the financing round.
Joseph F. Lovett, managing general partner of Louisiana Fund I, Ross P. Barrett, managing partner of Themelios Venture Partners and Chad Souvignier of RCT joined the Esperance board of directors.
Esperance is a start-up company based in Baton Rouge, La., that develops targeted and selective anticancer agents.
| Issuer: | Esperance Pharmaceuticals Inc.
|
| Issue: | Series A financing
|
| Amount: | $9 million
|
| Investors: | Louisiana Fund I, Themelios Ventures Partners LP and Research Corporation Technologies Inc. (co-lead)
|
| Announcement date: | Oct. 31
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
